GNOM vs IDNA
Global X Genomics & Biotechnology ETF against iShares Genomics Immunology and Healthcare ETF: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
30%
11 shared positions
Fee gap
3 bp
IDNA is cheaper
1-year return gap
6.5 pts
IDNA is ahead
Larger fund
IDNA
$320M
Side by side
| GNOM | IDNA | |
|---|---|---|
| Fund | Global X Genomics & Biotechnology ETF | iShares Genomics Immunology and Healthcare ETF |
| Issuer | Global X | iShares |
| Category | Biotech & Health Innovation | Biotech & Health Innovation |
| Expense ratio | 0.50% | 0.47% |
| Assets | $101M | $320M |
| Average daily dollar volume | $2.8M | $7.0M |
| Listed | Apr 5, 2019 | Jun 11, 2019 |
| FrenzyCap score | 50 | 61 |
| 1-month return | +10.9% | +11.3% |
| 3-month return | +23.6% | +28.0% |
| Year to date | +51.2% | +61.0% |
| 1-year return | +63.4% | +69.9% |
| 30-day volatility | 38.5% | 31.2% |
| Worst drawdown, 1 year | −18.2% | −10.7% |
| Trailing 12-month yield | 0.94% | 0.67% |
| Holdings | 52 | 63 |
| Top 10 weight | 55.9% | 48.1% |
| Look-through P/E | — | — |
| Holdings vs fair value | −2.4% | −3.9% |
| Holdings above 200-day average | 77% | 85% |
| Net flow, latest 3 reported months | +$1.4M thru May 2026 | +$15M thru Jul 2026 |
| 30-day implied volatility | 39.0% | 34.0% |
| Holdings as of | as of Oct 9, 2026issuer data | as of Oct 8, 2026issuer data |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
33% of GNOM · 33% of IDNA
Sector mix of the stock holdings
| Sector | GNOM | IDNA | Gap |
|---|---|---|---|
| Health Care | 79.4% | 80.3% | −0.9% |
| Technology | 15.0% | 3.6% | +11.4% |
| Financials | 0.0% | 2.6% | −2.6% |
More: full overlap table · GNOM holdings · IDNA holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.